Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 33: 1548-1553, 1987;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lentrichia, B. B.
Right arrow Articles by Yeung, K. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lentrichia, B. B.
Right arrow Articles by Yeung, K. K.

Clinical Chemistry, Vol 33, 1548-1553, Copyright © 1987 by American Association for Clinical Chemistry

Immunoassay of digoxin by differential centrifugation

BB Lentrichia, SJ Sciotto-Brown, MF Turanchik, IK Ropiak and KK Yeung

We describe an immunoassay of digoxin that exploits the differential sedimentation rate between two types of latex particles in a microcentrifugal analyzer. Conventional polystyrene latex particles (relative density = 1.05), sensitized with antibody, are first suspended with the sample and then mixed with digoxin-sensitized latex particles (relative density = 1.5). In the absence of digoxin in the sample, the two particle types bind to each other and, when subjected to centrifugal force, are cleared from the solution simultaneously. In the presence of digoxin, the binding between the particles is inhibited in proportion to the concentration of the drugs; the particles therefore can be differentially sedimented in 1 min. We measured the resulting absorbance to quantify the number of less-heavy particles and used the assay to generate a linear standard curve from 0 to 5 micrograms/L. Because the detection limit of the assay depends on the concentrations of both particle types, we optimized the assay by using two-dimensional analysis. Interference from rheumatoid factor was negligible up to 800 kilo-int. units/L. Precision studies indicated CVs between 5% and 13% within-run and between 4% and 9% for run-to-run in this endpoint assay.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by the American Association for Clinical Chemistry.